Tartis, Inc. is a discovery stage biotechnology company seeking novel anti-cancer and anti-aging drugs. Its proprietary technology is licensed from the laboratories of Professor Gudkov from Roswell Park Cancer Institute (Buffalo, NY).

Tartis, Inc. pipeline includes lead compounds for treatment of breast and prostate cancers, melanoma and hematological malignancies, as well as leads and drug candidates for delaying the development of age-related diseases (including cancer) and prolonging human life.